세계의 폐쇄형 약물 주입 기기(CSTD) 시장 : 유형, 구성요소, 폐쇄 메커니즘, 기술, 지역별 예측(-2032년)

Global Closed System Drug Transfer Device Market Research Report Information By type (Membrane to Membrane and Needleless System), By Component (Vial Access Devices, Syringe Safety Devices, Accessories, Bag/Line Access Devices), By Closing Mechanism (Push to Turn System, Color-to-color Alignment System, Leur Lock Systems, Click to Lock Systems), By Technology (Compartmentalize Devices, Diaphragm-Based Devices, and Air Filtration Devices) By Region- Forecast to 2032

Market Profile

The Closed System Drug Transfer Device Market is expected to have value USD 1.07 billion in 2023. From USD 1.20 billion in 2024 to USD 2.87 billion by 2032 the sector is expected to have a compound annual growth rate (CAGR) of 10.17%. The rigorous regulations of the healthcare industry and the worldwide increasing frequency of cancer are driving development in the market.

Importantly, the growing worldwide cancer prevalence is driving the global closed-system drug transfer device (CSTD) market. This is so because cancer therapy usually requires the use of dangerous drugs that could compromise the health of medical professionals handling them. By use of a closed and leak-proof mechanism, the device is meant to stop the release of these dangerous drugs into the surroundings. Furthermore driving the rising global cancer burden include environmental causes, aging population, better diagnosis tools, and lifestyle choices promoting market expansion.

Segregation of the market

Based on type, the worldwide closed-system drug transfer device market is divided into superfluous systems and membrane-to- membrane systems.

Four categories have been established out of the market: vial access devices, hypodermic safety devices, bag/line access devices, and accessories. The component grounds this division.

Four markets have been developed out of the market: push-to--turn systems, color-to--color alignment systems, leur lock systems, and click-to-lock systems. The closure mechanism forms basis for this classification.

Based on technology, the Closed System Drug Transfer Device Market now consists of air filtration devices, diaphragm-based devices, and compartmentalized devices.

The Market has been segmented into hospitals & clinics, specialty centers, and others based on the end consumer.

Geographic Insights

The Closed System Drug Transfer Device Market has been segmented into the Rest of the World, Asia-Pacific, Europe, and North America based on region. It is anticipated that North America will account for the largest market share in 2023 and reach USD 9.92 billion by 2032, with a compound annual growth rate (CAGR) of 9.10% during the forecast period.

The global CSTD market is expected to be dominated by North America, which holds the largest market share of 38.14%. The strong research and development infrastructure and the increasing prevalence of cancer cases are the primary factors contributing to this substantial market share. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer fatalities.

Asia-Pacific is anticipated to experience substantial growth and is anticipated to be the fastest-growing region during the forecast period. This is attributed to the growing number of new vendors involved in the drug-device system, as numerous regional and small market participants are attempting to leverage their market share.

The Closed System Drug Transfer Device Market is distinguished by the presence of numerous global, regional, and local vendors. The market is intensely competitive, with all participants striving to acquire the largest possible market share. Market growth is significantly influenced by intense competition, frequent changes in government policies, and regulations.

Major Players

Becton, Dickson, and Company, Inc., Baxter International Inc., ICU Medical, Inc., JMS Co.Ltd, B. Braun SE, Simplivia (Israel), Becton, Cormed (US), Yukon Medical (US), Caragen Ltd. (Ireland), and Equashield are among the major players in the Closed System Drug Transfer Device Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4. MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CANCER ACROSS THE GLOBE
  • 4.2.2 STRINGENT REGULATORY REQUIREMENTS WITHIN THE HEALTHCARE INDUSTRY
• 4.3 RESTRAINTS
  • 4.3.1.HIGH COST ASSOCIATED WITH CSTD
• 4.4 OPPORTUNITY
  • 4.4.1.GROWING TECHNOLOGICAL ADVANCEMENTS IN CLOSED SYSTEM DRUG TRANSFER DEVICES (CSTDS)

5.MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2.BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET

6.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 MEMBRANE-TO-MEMBRANE SYSTEMS
• 6.3.NEEDLELESS SYSTEM

7.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY COMPONENT

• 7.1 INTRODUCTION
• 7.2 SYRINGE SAFETY DEVICE
• 7.3 VIAL ACCESS DEVICES
• 7.4.ACCESSORIES
• 7.5 BAG/LINE ACCESS DEVICES

8.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY CLOSING MECHANISM

• 8.1 INTRODUCTION
• 8.2 PUSH TO TURN SYSTEM
• 8.3 COLOR-TO-COLOR ALIGNMENT SYSTEM
• 8.4 LEUR LOCK SYSTEMS
• 8.5.CLICK-TO-LOCK

9.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 COMPARTMENTALIZE DEVICES
• 9.3 DIAPHRAGM-BASED DEVICES
• 9.4 AIR FILTRATION DEVICES

10.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
• 10.3 SPECIALTY CENTERS
• 10.4 OTHERS

11.GLOBAL CLOSED SYSTEM DRUG TRANSFER DEVICES MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
  • 11.2.3 MEXICO
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 ITALY
  • 11.3.5 SPAIN
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA-PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 AUSTRALIA
  • 11.4.6 REST OF ASIA-PACIFIC
• 11.5 REST OF THE WORLD
  • 11.5.1 MIDDLE EAST
  • 11.5.2 AFRICA
  • 11.5.3 LATIN AMERICA

12.COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 MARKET SHARE ANALYSIS,
• 12.3 COMPETITOR DASHBOARD
• 12.4 PUBLIC PLAYERS STOCK SUMMARY
• 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.6.1 PRODUCT LAUNCH
  • 12.6.2 PRODUCT APPROVAL

13.COMPANY PROFILES

• 13.1 B. BRAUN SE
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 JMS CO.LTD.
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 KEY STRATEGIES
• 13.3 ICU MEDICAL, INC.
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCT OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 SWOT ANALYSIS
  • 13.3.6 KEY STRATEGIES
• 13.4 SIMPLIVIA
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 EQUASHIELD
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCTS OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 BD
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 BAXTER
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 CORMED
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 YUKON MEDICAL
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 SWOT ANALYSIS
  • 13.9.6 KEY STRATEGIES
• 13.13.CARAGEN LTD
  • 13.13.1 COMPANY OVERVIEW
  • 13.13.2 FINANCIAL OVERVIEW
  • 13.13.3 PRODUCTS OFFERED
  • 13.13.4 KEY DEVELOPMENTS
  • 13.13.5 KEY STRATEGIES

14 DATA CITATIONS